CTLA4 and neoplasm: However, when administrating CTLA-4 inhibitor during vaccination, a higher frequency of NY-ESO-1-specific effector CD8+ T cells producing IFN-γ was evident and more lymphocytes migrated and infiltrated the tumor microenvironment (TME), resulting in the prevention of tumor progression and extended survival of tumor-bearing mice [175].